
Piramal Enterprises Limited (PEL) saw its shares rise by nearly 5% in early trade on January 14, following news that the company could receive up to $200 million from its divested arm, Piramal Imaging SA.
The stock traded at ₹992.95, reflecting a significant gain from the previous close of ₹947.90.
Potential Earnings Breakdown: The company, through its subsidiary, is set to receive an estimated $140 million in FY26 as part of the sale of Life Molecular Imaging by Life Healthcare Group Holdings. Additional amounts may be earned in the coming years based on eligible profits and future earnouts, with a total potential payout capped at $200 million, including the $140 million upfront payment.
Background: Life Healthcare Group Holdings had earlier acquired Piramal Imaging SA from Piramal Enterprises in 2018. Recently, Life Healthcare entered into binding agreements for the sale of Life Molecular Imaging, a key member of the Imaging Group. This strategic move has unlocked value for PEL, reflecting the company’s successful divestment strategy.
Market Reaction: Investors reacted positively to the announcement, pushing PEL’s stock up nearly 5%. The company’s market capitalization now stands at ₹220.41 billion. Analysts see this as a significant boost to PEL’s balance sheet, further strengthening its financial position.
Piramal Enterprises Share Price history
Day | Open | Close | Change % |
---|---|---|---|
Mon, Jan 13 2025
|
₹987.85
|
₹947.90
|
-4.04%
|
Fri, Jan 10 2025
|
₹1,031.00
|
₹987.85
|
-4.28%
|
Thu, Jan 9 2025
|
₹1,046.95
|
₹1,032.05
|
-1.51%
|
Wed, Jan 8 2025
|
₹1,060.00
|
₹1,047.85
|
-1.16%
|
Tue, Jan 7 2025
|
₹1,043.10
|
₹1,060.20
|
|
Mon, Jan 6 2025
|
₹1,095.80
|
₹1,047.10
|
-4.45%
|
Fri, Jan 3 2025
|
₹1,125.00
|
₹1,095.85
|
-2.63%
|
Thu, Jan 2 2025
|
₹1,094.70
|
₹1,125.45
|
|
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.